KemPharm Reports Positive Results from Trial

KemPharm Reports Positive Results from Trial

KemPharm has reported positive results from a study to assess KP511 Active Pharmaceutical Ingredient (API) compared to equivalent doses of hydromorphone hydrochloride (HM API). KP511 is KemPharm’s investigational prodrug of hydromorphone to treat pain. The company said that KP511 demonstrated statistically significant reduction in peak and overall hydromorphone exposure with KP511 API versus HM API. “This study provides very strong preliminary evidence that KP511 imparts significant potential for deterring intranasal […]

Read More ˃
Intersect ENT Reports Preliminary Q4 Revenue Above Street View

Intersect ENT Reports Preliminary Q4 Revenue Above Street View

Intersect ENT advanced in morning trading on Monday after the commercial stage drug-device company pre-announced higher-than-estimated Q4 revenue and guided for Q1 revenue nearly in line with the Street view. Shares rose more than 2%. Preliminary unaudited revenue for Q4 is expected to be in the range of $24.0 to $24.2 million, an increase of 28% compared to $18.8 million for the year-ago period. That topped the $23.08 million of […]

Read More ˃